A MAJOR BREAKTHROUGH MAY BE RIGHT IN FRONT OF US
BIEL just moved into lean, stripped-down offices with zero storage. Companies don’t do that unless they’re shifting to a new operating model. This screams partnership pivot.
They filed FDA Registration for 2026 early. EARLY.
BIEL has never been early. Something big is being prepped behind the curtain.
The ACCESS program (backed by AMA, ACC, APA, Dr. Oz) is pouring gasoline on the tech-for-healthcare movement—BIEL is perfectly positioned to ride that wave.
ACCESS requires proven patient outcomes for reimbursement. BIEL’s electroceutical tech is literally designed for repeatable, measurable improvements.
Electrome is building an AI-powered bioelectric therapy platform for a $152 BILLION market. Their entire model fits seamlessly on top of BIEL’s FDA-cleared foundation.
The growing theory:
👉 Electrome licensed BIEL tech.
👉 Electrome licensed BIEL FDA clearances.
👉 This is NOT a manufacturing deal—this is a technology integration.
The downsized office + no inventory + CICD out =
BIEL quietly stepping into a new role as the IP + regulatory backbone for a massive 2026 launch.
Dr. Nigel Timothy:
Heavily invested in BIEL
Holds key debt
Consultant at Electrome
The man is positioned EXACTLY where he’d be if a merger/licensing combo were in motion.
Keith Nalepka + CMMS reimbursement codes getting mentioned now?
You don't tease reimbursement unless you’re preparing for national-scale distribution.
Add it all up:
Regulators lined up. Policies lined up. Partners lined up. Market timing perfect.
This is the strongest setup BIEL has EVER had.
The puzzle pieces don’t just fit…
Market Data 
Markets 
